Fujifilm Hldgs Corp (FUJIY) 29.5700 $FUJIY
How Will Fujifilm (FUJIY) Stock Be Boosted By Ebola Drug Approval?
at The Street - Thu Aug 07, 11:54AM CDT
U.S. government researchers are working to get an experimental flu drug from the Japan-based company quickly approved to treat Ebola.
Fujifilm's Q1 Earnings Rise; Revenues Drop Year over Year - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:35AM CDT
Fujifilm (FUJIY) reports mixed results for fiscal first-quarter 2015, with year over year improvement in net income while revenues declined.
TriQuint Beats on Q2 Earnings; Bullish Outlook for 2H14 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:20PM CDT
TriQuint (TQNT) reported adjusted earnings of 13 cents per share, beating the Zacks Consensus Estimate of 3 cents. The company benefited from its portfolio restructuring efforts toward higher-value solutions.
Why FUJIFILM Holdings (FUJIY) is Such a Great Value Stock Pick Right Now - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:37AM CDT
FUJIFILM Holdings (FUJIY) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and of late, it is seeing solid earnings estimate revisions as well.
Fujifilm Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 9:30AM CDT
Zacks Investment Research upgraded Fujifilm Holdings (FUJIY) to a Zacks Rank #1 (Strong Buy) on Jul 9, based on its efforts to innovate technologies.
FUJIFILM Supports Warrior Hike as New Sponsor
Business Wire - Wed Apr 02, 9:28AM CDT
FUJIFILM Holdings America Corporation is delighted to announce its sponsorship of Warrior Hike, a non-profit organization supporting combat veterans transitioning from their military service by hiking America's National Scenic Trails.
Melvin: Keep It Simple
at The Street - Fri Mar 21, 2:30PM CDT
You only need to ask these two questions when selecting a stock.
Risk-Wary Investors Deal Nippon Stocks A Harsh Blow
at Investor's Business Daily - Fri Mar 14, 4:42PM CDT
While U.S. markets lodged a disappointing week, markets overseas put in some of the worst performances in a year. The Tokyo Stock Exchange was hardest hit among those, with the Nikkei 225 tumbling 3.3% Friday -- leaving the index down 6.2% in its...
Updated Research Report on Fujifilm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 6:15PM CST
On Feb 27, 2014, we issued an updated research report on Fujifilm Holdings Corporation.
Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
Fujifilm's Q3 Earnings Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 1:00PM CST
Fujifilm reports improved year-over-year results in the third quarter of fiscal 2014.
Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.
Global Mammography Equipment Market 2014-2018: Market Witnessing the Growing use of 3D Mammography
M2 - Thu Jan 16, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/pq3pxr/global) has announced the addition of the "Global Mammography Equipment Market 2014-2018" report to their offering. The analysts forecast the Global Mammography Equipment market to grow at a CAGR of 9.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of breast cancer. The Global Mammography Equipment Market 2014-2018 has also been witnessing the growing use of 3D mammography. However, the high cost of mammography equipment could pose a challenge to the growth of this market. Key vendors dominating this space are FUJIFILM Holdings Corp., GE Healthcare, Hologic Inc., Phillips Healthcare, and Siemens Healthcare. Other vendors mentioned in the report are Carestream Health Inc., Internazionale Medico Scientifica Srl, PerkinElmer Inc., Planmed Oy and Toshiba Medical Systems Corp. Commenting on the report, an analyst from the team said: With technological advancements, there has been an increase in the use of 3D mammography globally in recent years. The 3D mammography system is considered to be 7 percent more accurate compared to the traditional 2D mammography system. The 3D mammography system is currently available for commercial use in Latin America, Europe, and Asia. There is currently only one product available though, which is Selenia Dimensions 3D tomosynthesis offered by Hologic Inc. It was approved for sale in the US by the FDA on February 11, 2011 and has generated the maximum revenue for Hologic Inc. in the US. The introduction of new generation mammography equipment has enhanced the efficiency of breast cancer surgeries and treatments. 3D mammography removes overlapping tissue artifacts, especially in dense breasts and offers better screening sensitivity. Thus, the growing use of 3D mammography is expected to drive growth in the Global Mammography Equipment market. According to the report, the Global Mammography Equipment market is driven by several factors. One of the main drivers in this market is the increasing incidence of breast cancer among women which has led to an increase in the demand for mammography equipment for the accurate diagnosis of breast cancer. For more information visit http://www.researchandmarkets.com/research/pq3pxr/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fujifilm Eyes Growth Through Portfolio Boost - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 5:30PM CST
Fujifilm Holdings has been attempting to grow with product launches.
Pipeline Progress at Cempra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 4:00PM CST
Cempra recently initiated a phase III trial on antibiotic candidate, solithromycin.
Global Small Animal Imaging Market Report 2013-2017
PR Newswire Europe - Wed Dec 11, 12:11PM CST
DUBLIN, Dec. 11, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/94fx8f/small_animal [http://www.researchandmarkets.com/research/94fx8f/small_animal]) has announced the addition of the "Global Small Animal Imaging Market Report 2013-2017" [http://www.researchandmarkets.com/research/94fx8f/small_animal] report to their offering.
Fujifilm Downgraded to Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 16, 11:50AM CDT
On Sep 13, 2013, we downgraded our recommendation on Fujifilm Holdings Corporation to Neutral from Outperform.
Data on Cempra's Solithromycin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 06, 3:25PM CDT
Cempra, Inc. announced that solithromycin, showed safety and tolerability in patients.
FUJIFILM Announces Executive Changes in North America
Business Wire - Wed Sep 04, 8:15AM CDT
--Shigeru Sano appointed President of FUJIFILM Holdings America Corporation
Overall Pre-Clinical Imaging (In Vivo) Market Valued at $790 Million in 2012, and is Estimated to Grow at an Annual Growth Rate of 14.5% Up To 2017
M2 - Thu Aug 29, 11:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h4zgzn/preclinical) has announced the addition of the "Pre-Clinical Imaging (In vivo) Market - By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017" report to their offering. In 2012, North America is the biggest market, about 38.2% share of the global pre-clinical imaging (in vivo) systems and reagents market, followed by Europe. However, the Asian and Latin American countries represent the fastest growing markets due to increasing government support for research, growing number of research institution and CRO's, and rising industry-academia partnerships for pre-clinical research. Moreover, economic slowdown, pricing pressures and high competition in mature countries will compel the companies to focus on the Asian market. Pre-clinical imaging technologies are excellent tools for assessment of anatomical, physiological and functional parameters at molecular and cellular levels in the live animal models. It plays a significant role in the assessment of specific drug candidate or treatment regime, in phenotyping and understanding the pathophysiology of various diseases. The global pre-clinical imaging (in vivo) market has witnessed challenging and dynamic market conditions in terms of government funding/grants and technological advancements in the last five years. The overall pre-clinical imaging (in vivo) market is valued at $790 million in 2012, and is estimated to grow at an annual growth rate of 14.5% over the next five years. Market displays growing preference for new technologies such as hybrid systems - PET MRI, SPECT MRI and PET SPECT CT, for the continuum of advantages offered by them over traditional standalone techniques as they enable to overcome limitations of each technology. Pre-clinical imaging (in vivo) industry has witnessed myriad technological advancements over the last two decades and it is expected that this trend will continue in future to solve the present challenges and fill the unmet needs of the market. Pre-clinical imaging market is highly competitive, with each player vying to make a mark and gain a large market share. Rapid industry consolidation is a burning issue in the market currently, which not only affects the small market players but also enforces big players to redefine their marketing strategies. Companies Mentioned: - Aspect Imaging (Israel) - Bioscan - Bruker Corporation (U.S.) - FUJIFILM Holdings Corporation (Japan) - Gamma Medica (U.S.) - Life Technologies Corporation (U.S.) - Mediso Medical Imaging Systems (Hungary) - Miltenyi Biotec GmbH (Germany) - PerkinElmer - Scanco Medical (Switzerland) - Siemens AG (Germany) - Targeson For more information visit http://www.researchandmarkets.com/research/h4...reclinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
How Will Fujifilm (FUJIY) Stock Be Boosted By Ebola Drug Approval?
at The Street - Thu Aug 07, 11:54AM CDT
U.S. government researchers are working to get an experimental flu drug from the Japan-based company quickly approved to treat Ebola.
Fujifilm's Q1 Earnings Rise; Revenues Drop Year over Year - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:35AM CDT
Fujifilm (FUJIY) reports mixed results for fiscal first-quarter 2015, with year over year improvement in net income while revenues declined.
TriQuint Beats on Q2 Earnings; Bullish Outlook for 2H14 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:20PM CDT
TriQuint (TQNT) reported adjusted earnings of 13 cents per share, beating the Zacks Consensus Estimate of 3 cents. The company benefited from its portfolio restructuring efforts toward higher-value solutions.
Why FUJIFILM Holdings (FUJIY) is Such a Great Value Stock Pick Right Now - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:37AM CDT
FUJIFILM Holdings (FUJIY) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and of late, it is seeing solid earnings estimate revisions as well.
Fujifilm Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 9:30AM CDT
Zacks Investment Research upgraded Fujifilm Holdings (FUJIY) to a Zacks Rank #1 (Strong Buy) on Jul 9, based on its efforts to innovate technologies.
FUJIFILM Supports Warrior Hike as New Sponsor
Business Wire - Wed Apr 02, 9:28AM CDT
FUJIFILM Holdings America Corporation is delighted to announce its sponsorship of Warrior Hike, a non-profit organization supporting combat veterans transitioning from their military service by hiking America's National Scenic Trails.
Melvin: Keep It Simple
at The Street - Fri Mar 21, 2:30PM CDT
You only need to ask these two questions when selecting a stock.
Risk-Wary Investors Deal Nippon Stocks A Harsh Blow
at Investor's Business Daily - Fri Mar 14, 4:42PM CDT
While U.S. markets lodged a disappointing week, markets overseas put in some of the worst performances in a year. The Tokyo Stock Exchange was hardest hit among those, with the Nikkei 225 tumbling 3.3% Friday -- leaving the index down 6.2% in its...
Updated Research Report on Fujifilm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 6:15PM CST
On Feb 27, 2014, we issued an updated research report on Fujifilm Holdings Corporation.
Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
Fujifilm's Q3 Earnings Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 1:00PM CST
Fujifilm reports improved year-over-year results in the third quarter of fiscal 2014.
Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.
Global Mammography Equipment Market 2014-2018: Market Witnessing the Growing use of 3D Mammography
M2 - Thu Jan 16, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/pq3pxr/global) has announced the addition of the "Global Mammography Equipment Market 2014-2018" report to their offering. The analysts forecast the Global Mammography Equipment market to grow at a CAGR of 9.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of breast cancer. The Global Mammography Equipment Market 2014-2018 has also been witnessing the growing use of 3D mammography. However, the high cost of mammography equipment could pose a challenge to the growth of this market. Key vendors dominating this space are FUJIFILM Holdings Corp., GE Healthcare, Hologic Inc., Phillips Healthcare, and Siemens Healthcare. Other vendors mentioned in the report are Carestream Health Inc., Internazionale Medico Scientifica Srl, PerkinElmer Inc., Planmed Oy and Toshiba Medical Systems Corp. Commenting on the report, an analyst from the team said: With technological advancements, there has been an increase in the use of 3D mammography globally in recent years. The 3D mammography system is considered to be 7 percent more accurate compared to the traditional 2D mammography system. The 3D mammography system is currently available for commercial use in Latin America, Europe, and Asia. There is currently only one product available though, which is Selenia Dimensions 3D tomosynthesis offered by Hologic Inc. It was approved for sale in the US by the FDA on February 11, 2011 and has generated the maximum revenue for Hologic Inc. in the US. The introduction of new generation mammography equipment has enhanced the efficiency of breast cancer surgeries and treatments. 3D mammography removes overlapping tissue artifacts, especially in dense breasts and offers better screening sensitivity. Thus, the growing use of 3D mammography is expected to drive growth in the Global Mammography Equipment market. According to the report, the Global Mammography Equipment market is driven by several factors. One of the main drivers in this market is the increasing incidence of breast cancer among women which has led to an increase in the demand for mammography equipment for the accurate diagnosis of breast cancer. For more information visit http://www.researchandmarkets.com/research/pq3pxr/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fujifilm Eyes Growth Through Portfolio Boost - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 5:30PM CST
Fujifilm Holdings has been attempting to grow with product launches.
Pipeline Progress at Cempra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 4:00PM CST
Cempra recently initiated a phase III trial on antibiotic candidate, solithromycin.
Global Small Animal Imaging Market Report 2013-2017
PR Newswire Europe - Wed Dec 11, 12:11PM CST
DUBLIN, Dec. 11, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/94fx8f/small_animal [http://www.researchandmarkets.com/research/94fx8f/small_animal]) has announced the addition of the "Global Small Animal Imaging Market Report 2013-2017" [http://www.researchandmarkets.com/research/94fx8f/small_animal] report to their offering.
Fujifilm Downgraded to Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 16, 11:50AM CDT
On Sep 13, 2013, we downgraded our recommendation on Fujifilm Holdings Corporation to Neutral from Outperform.
Data on Cempra's Solithromycin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 06, 3:25PM CDT
Cempra, Inc. announced that solithromycin, showed safety and tolerability in patients.
FUJIFILM Announces Executive Changes in North America
Business Wire - Wed Sep 04, 8:15AM CDT
--Shigeru Sano appointed President of FUJIFILM Holdings America Corporation
Overall Pre-Clinical Imaging (In Vivo) Market Valued at $790 Million in 2012, and is Estimated to Grow at an Annual Growth Rate of 14.5% Up To 2017
M2 - Thu Aug 29, 11:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h4zgzn/preclinical) has announced the addition of the "Pre-Clinical Imaging (In vivo) Market - By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017" report to their offering. In 2012, North America is the biggest market, about 38.2% share of the global pre-clinical imaging (in vivo) systems and reagents market, followed by Europe. However, the Asian and Latin American countries represent the fastest growing markets due to increasing government support for research, growing number of research institution and CRO's, and rising industry-academia partnerships for pre-clinical research. Moreover, economic slowdown, pricing pressures and high competition in mature countries will compel the companies to focus on the Asian market. Pre-clinical imaging technologies are excellent tools for assessment of anatomical, physiological and functional parameters at molecular and cellular levels in the live animal models. It plays a significant role in the assessment of specific drug candidate or treatment regime, in phenotyping and understanding the pathophysiology of various diseases. The global pre-clinical imaging (in vivo) market has witnessed challenging and dynamic market conditions in terms of government funding/grants and technological advancements in the last five years. The overall pre-clinical imaging (in vivo) market is valued at $790 million in 2012, and is estimated to grow at an annual growth rate of 14.5% over the next five years. Market displays growing preference for new technologies such as hybrid systems - PET MRI, SPECT MRI and PET SPECT CT, for the continuum of advantages offered by them over traditional standalone techniques as they enable to overcome limitations of each technology. Pre-clinical imaging (in vivo) industry has witnessed myriad technological advancements over the last two decades and it is expected that this trend will continue in future to solve the present challenges and fill the unmet needs of the market. Pre-clinical imaging market is highly competitive, with each player vying to make a mark and gain a large market share. Rapid industry consolidation is a burning issue in the market currently, which not only affects the small market players but also enforces big players to redefine their marketing strategies. Companies Mentioned: - Aspect Imaging (Israel) - Bioscan - Bruker Corporation (U.S.) - FUJIFILM Holdings Corporation (Japan) - Gamma Medica (U.S.) - Life Technologies Corporation (U.S.) - Mediso Medical Imaging Systems (Hungary) - Miltenyi Biotec GmbH (Germany) - PerkinElmer - Scanco Medical (Switzerland) - Siemens AG (Germany) - Targeson For more information visit http://www.researchandmarkets.com/research/h4...reclinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
